Clinical Guides
Colorectal Cancer
A clinically focused, India-adapted guide to recognising, confirming, staging and coordinating multidisciplinary care for colon and rectal cancer, with explicit limits on applying older Indian consensus and foreign pathways.
MedNext Academy | 13 min read
Colorectal Cancer
A clinically focused, India-adapted guide to recognising, confirming, staging and coordinating multidisciplinary care for colon and rectal cancer, with explicit limits on applying older Indian consensus and foreign pathways.
Summary
Colorectal cancer comprises malignant epithelial tumours arising in the colon or rectum; most are adenocarcinomas developing through chromosomal-instability, mismatch-repair or serrated pathways. Anatomical site matters. Colon cancer commonly presents with occult bleeding, iron-deficiency anaemia, altered bowel habit, pain or obstruction, whereas rectal cancer more often causes visible bleeding, tenesmus, urgency or a palpable lesion. These patterns overlap, and neither young age nor the absence of pain excludes disease. A diagnosis requires histopathology, not a tumour marker or scan alone. Initial work-up defines fitness, synchronous lesions, TNM stage and tumour biology. Complete colonic evaluation, contrast-enhanced staging imaging and, for rectal cancer, high-quality pelvic MRI should feed a specialist multidisciplinary discussion. CEA is useful as a baseline prognostic and surveillance marker when interpreted in context, but is neither sufficiently sensitive nor specific for diagnosis. Curative treatment usually centres on oncological resection; rectal cancer frequently needs preoperative systemic therapy and/or radiotherapy selected by MRI-defined risk. Adjuvant treatment depends on pathological stage and recurrence risk. Metastatic disease is heterogeneous: some liver- or lung-limited disease remains potentially curable, while unresectable disease requires biomarker-directed systemic and supportive care. The 2014 ICMR consensus supplies India-specific foundations but predates several current molecular treatments; therefore its treatment details must be reconciled with contemporary evidence, Indian approvals, local formularies and tumour-board judgement rather than copied as a fixed protocol.
How Common Is It?
Colorectal cancer is a major global cancer but its burden is not distributed evenly. The World Health Organization reports approximately 1.9 million new cases and more than 900,000 deaths worldwide in 2022, while also noting increasing disease among some adults aged 30 to 50 years. Those global figures must not be converted into an Indian incidence estimate. Indian population-based cancer registries show substantial geographic, urban-rural and sex variation, and registry coverage is not identical to a complete national census. The ICMR-NCDIR 2020 report therefore supports comparing registry-specific incidence patterns and trends rather than claiming that every Indian state has one uniform rate. The older 2014 ICMR colorectal consensus described lower recorded incidence than in many Western settings alongside urbanisation-related increases; its numeric rates were based on earlier registry periods and should not be presented as current 2026 surveillance. Clinically, a lower population rate does not justify dismissing persistent rectal bleeding, unexplained iron-deficiency anaemia, progressive bowel change, weight loss or an abdominal mass. Case mix also differs by referral centre: tertiary oncology hospitals see later-stage and more complex disease than community practice. Screening intensity, endoscopy access, awareness and competing causes of anaemia influence observed presentation. A responsible guide therefore separates global burden, historical Indian observations and local service data, dates every estimate, and avoids implying that registry figures predict one patient’s probability of cancer.
Risk Factors
Age is the strongest population-level risk factor, but colorectal cancer can occur in younger adults. Risk rises with a previous advanced adenoma or colorectal cancer, a first-degree family history, long-standing colonic inflammatory bowel disease and inherited syndromes. Lynch syndrome results from pathogenic mismatch-repair pathway variants; familial adenomatous polyposis and related polyposis syndromes require distinct genetic and endoscopic pathways. Multiple affected relatives, early-onset disease, synchronous or metachronous tumours, or a family pattern involving endometrial and other Lynch-associated cancers should trigger careful pedigree assessment and genetics referral where available. Modifiable associations include tobacco, alcohol, obesity, physical inactivity, and dietary patterns high in processed meat and low in plant foods. These are risk associations, not diagnostic tests, and counselling should avoid blaming patients. Type 2 diabetes and prior abdominopelvic radiation can add risk in some settings. In inflammatory bowel disease, duration, extent, inflammatory activity, family history and previous dysplasia shape surveillance; average-risk screening rules must not be substituted. Conversely, haemorrhoids, vegetarian diet or absence of family history do not rule cancer out. Medication and surgical histories matter because iron supplementation can darken stool, anticoagulants can unmask bleeding, and previous colorectal surgery changes anatomy. A clinician should use risk to adjust urgency and prevention, never to withhold evaluation from a symptomatic person. Foreign age-based screening recommendations cannot automatically define Indian policy, because programme resources, background incidence and follow-up capacity differ.
Diagnosis
History
Clarify the onset and trajectory of rectal bleeding, melaena-like stool, altered frequency or calibre, urgency, tenesmus, abdominal pain, distension, vomiting, fatigue, weight loss and appetite change. Ask about iron deficiency, previous polyps, inflammatory bowel disease, abdominal radiation, operations, medicines and a three-generation cancer history. Record functional status, frailty, nutrition and comorbidities because they affect investigation and treatment.
Examination
Assess haemodynamic stability, pallor, hydration, wasting, abdominal distension, tenderness, masses, ascites, hepatomegaly and lymphadenopathy. Inspect the perianal region and perform digital rectal examination when appropriate, documenting a mass, its distance and mobility. A normal rectal examination cannot exclude a proximal tumour. Acute peritonism or obstruction changes the pathway from outpatient evaluation to emergency surgical assessment.
Investigations
Obtain full blood count with indices, renal and liver profiles and other tests directed by illness severity. Confirm iron deficiency rather than labelling every microcytosis as gastrointestinal blood loss. Colonoscopy with biopsies is the usual definitive luminal investigation and should assess the remaining colon for synchronous pathology; CT colonography or planned postoperative completion may be needed when a stenosis prevents passage. Histology establishes cancer type. Record baseline CEA for prognosis and follow-up, not diagnosis. Contrast-enhanced CT of chest, abdomen and pelvis stages distant disease. Rectal tumours require protocolled pelvic MRI for local staging and resection-plane assessment. Molecular testing, including mismatch-repair or microsatellite-instability status and metastatic-disease biomarkers, should be selected and interpreted by the treating oncology team.
Differential Diagnosis
Rectal bleeding is often attributed to haemorrhoids or fissure, but an anorectal source does not exclude a synchronous proximal lesion, especially when anaemia, bowel change or weight loss coexists. Diverticular disease can cause bleeding, pain or altered habit; diverticulitis usually has an inflammatory presentation and imaging pattern. Infective colitis, inflammatory bowel disease, ischaemic colitis and drug-related injury can produce diarrhoea and blood, with tempo, exposures, endoscopy and histology distinguishing them. Tuberculosis of the intestine remains an important Indian mimic of ileocaecal malignancy, as do Crohn disease, amoeboma and appendicular or caecal inflammatory masses. Benign adenomas may bleed and carry malignant potential but cannot be reliably classified by symptoms. Irritable bowel syndrome may cause pain and altered stool form, yet does not explain objective iron deficiency, a mass, nocturnal progressive symptoms or constitutional decline. Upper gastrointestinal bleeding can present as dark stool or iron deficiency; gynaecological blood loss and nutritional deficiency may explain anaemia in some patients but should be verified, not assumed. Other malignancies include anal squamous cancer, small-bowel cancer, lymphoma, gastrointestinal stromal tumour, ovarian cancer invading bowel and metastatic deposits. In obstruction, faecal impaction, volvulus, adhesions and benign stricture must be considered urgently. The goal is not an exhaustive list: it is to recognise features that require colon evaluation and to avoid anchoring on a common benign diagnosis before explaining the whole clinical picture.
Management
Every confirmed case should be discussed in a colorectal multidisciplinary team that integrates pathology, radiology, gastroenterology, colorectal surgery, medical oncology, radiation oncology, genetics, stoma care, nutrition and palliative expertise as relevant. Remove suitable malignant polyps endoscopically only when pathological criteria and margins permit; otherwise offer oncological resection. Localised colon cancer is usually treated with segmental colectomy and regional lymphovascular clearance. Pathology must report depth, nodes examined and involved, margins, grade, lymphovascular or perineural invasion, deposits and relevant molecular findings. Stage III disease generally warrants adjuvant fluoropyrimidine-based chemotherapy with oxaliplatin when appropriate; selected high-risk stage II cases require individual discussion. Rectal care is driven by MRI-defined height, mesorectal fascia, nodal disease, extramural venous invasion and sphincter considerations. Total mesorectal excision principles, preoperative radiotherapy and systemic therapy are combined according to risk, not used identically for every rectal tumour. Early lesions may be suitable for local excision within strict criteria. For metastatic disease, define resectability repeatedly: selected liver, lung or peritoneal metastases may enter curative-intent pathways, whereas unresectable disease needs systemic therapy chosen by fitness, symptoms, sidedness and tumour biomarkers. Manage obstruction, perforation, bleeding, pain and nutrition promptly; a stoma may be lifesaving or function-preserving rather than treatment failure. Shared decisions must cover cure probability, recurrence, bowel and sexual function, fertility, neuropathy, stoma outcomes, cost and travel. The ICMR 2014 algorithms are educational foundations, not a substitute for current institutional protocols.
Prescribing Information
Anticancer medicines must be prescribed through oncology protocols with verified diagnosis, stage, organ function, performance status, interactions and biomarker eligibility. Fluoropyrimidines such as 5-fluorouracil or capecitabine underpin common adjuvant and metastatic regimens; oxaliplatin adds cumulative sensory neuropathy, while irinotecan can cause severe diarrhoea and myelosuppression. Before a fluoropyrimidine, assess local policy for dihydropyrimidine dehydrogenase deficiency testing and counsel about urgent toxicity, because profound early diarrhoea, mucositis, cytopenia, neurotoxicity or cardiotoxic symptoms may signal dangerous exposure. Capecitabine dosing requires renal assessment and adherence review. Antiemesis, venous-access care and infection instructions are integral, not optional extras. Targeted treatment is conditional: anti-EGFR therapy requires an appropriate RAS-wild-type context and is influenced by primary-tumour sidedness and other molecular features; anti-angiogenic medicines carry hypertension, bleeding, thrombotic, wound-healing and perforation risks. Immune-checkpoint therapy may be appropriate for mismatch-repair-deficient or microsatellite-instability-high advanced disease, but immune toxicities can affect any organ and require rapid specialist assessment. Do not infer eligibility from family history or tumour location. Rectal radiotherapy and concurrent systemic treatment need radiation-oncology planning. Analgesia, thrombosis management, iron replacement, bowel care and antibiotics should address a defined indication and be coordinated around surgery or chemotherapy. Exact regimens, doses, cycles and funding routes change; verify current Indian product approval, formulary, protocol and pharmacovigilance requirements before prescribing.
When to Refer
Refer suspected colorectal cancer for prompt specialist evaluation when rectal bleeding is persistent or unexplained, particularly with altered bowel habit, iron-deficiency anaemia, weight loss, an abdominal or rectal mass, or a relevant family history. Do not use one age cut-off to cancel concern in a younger adult. Confirmed or strongly suspected disease should enter a gastroenterology or colorectal surgical pathway capable of biopsy, staging and tumour-board review. Refer urgently to an emergency surgical service for obstruction, perforation, peritonitis, uncontrolled bleeding, sepsis or clinical deterioration. Once cancer is confirmed, early medical-oncology and, for rectal disease, radiation-oncology involvement prevents sequential decisions that compromise resectability. Refer to clinical genetics for suspected Lynch syndrome, polyposis, early-onset disease or a strong clustered family history; tumour mismatch-repair findings can also prompt this pathway. Stoma specialists should counsel before a planned stoma whenever time permits, with postoperative access arranged. Nutrition referral is appropriate for weight loss, sarcopenia, poor intake or obstructive dietary restriction. Palliative care should be introduced according to symptom and decision-support need, including during active anticancer treatment, rather than reserved for the final days. Fertility, sexual health, rehabilitation and psycho-oncology services should be offered when relevant. Referral timing in India must reflect local capacity without normalising unsafe delay: document the urgency, provide safety-net symptoms, communicate results directly and help patients navigate an accessible centre rather than merely issuing an untracked referral slip.
Red Flags
Immediate escalation is required for severe colicky pain with progressive distension, vomiting and failure to pass stool or flatus, which suggests large-bowel obstruction. Peritonism, fever, tachycardia, hypotension, free air or sudden worsening raises concern for perforation and sepsis. Ongoing brisk rectal bleeding, syncope, haemodynamic compromise or rapidly falling haemoglobin requires resuscitation and urgent source control. A tender irreducible prolapsed lesion, severe post-procedure pain, or clinical toxicity after colonoscopy or surgery also needs emergency assessment. During systemic therapy, fever or rigors, profound diarrhoea, repeated vomiting, inability to drink, new chest pain, breathlessness, confusion, reduced urine, bleeding, or painful swollen limb may represent neutropenic sepsis, dehydration, fluoropyrimidine cardiotoxicity, thrombosis or another treatment emergency. After colorectal surgery, increasing abdominal pain, tachycardia, fever, ileus, purulent or faeculent drainage and unexplained organ dysfunction can indicate an anastomotic leak even without dramatic examination findings. New jaundice, rapidly increasing ascites, focal neurological deficit, severe back pain with weakness or bladder disturbance, or uncontrolled cancer pain requires urgent assessment for progression or compression. A red flag is an action trigger, not proof of malignancy. Stabilise airway, breathing and circulation, obtain senior surgical or oncology input, and avoid delaying treatment for a routine outpatient test. Patients and carers need written, locally usable instructions on whom to contact around the clock.
Indian Clinical Context
Indian care spans public hospitals, charitable centres and private networks with marked variation in endoscopy, pathology, pelvic MRI, molecular testing, radiotherapy and specialist colorectal surgery. The ICMR 2014 consensus is valuable because it explicitly considered available versus desirable investigations, nutrition, cost and Indian multidisciplinary practice. It is also more than a decade old and reviewed literature largely through 2012; it predates important changes in immunotherapy, molecular selection, total neoadjuvant strategies and supportive care. Use it to understand Indian foundations and constraints, then reconcile each treatment decision with current evidence, Indian regulatory status and the receiving centre’s protocol. ICMR-NCDIR registry reports describe selected populations and should not be used to promise one national incidence rate or individual prognosis. Do not assume a uniform nationwide screening pathway, referral interval or entitlement. Symptomatic evaluation must proceed on clinical need, while screening or surveillance should follow a documented programme appropriate to family risk, inflammatory bowel disease and local capacity. Resource stewardship means choosing tests that will change management, not denying essential staging. Where pelvic MRI, expert pathology or biomarker testing is unavailable, arrange referral or documented multidisciplinary alternatives before irreversible treatment. Discuss travel, accommodation, lost wages, stoma-supply continuity and medicine affordability openly. Provide reports, images, blocks and treatment summaries that another centre can use. Linguistically appropriate consent should cover bowel, urinary and sexual outcomes and the possibility of a stoma. This guide is educational and cannot define a hospital’s oncology protocol.
NMC Competency Mapping
The NMC CBME Curriculum 2024 explicitly maps colon carcinoma within Pathology competency PA23.8: the learner should describe its aetiology, pathogenesis, pathology and distinguishing features. PA23.9 extends the learning task to describing and identifying microscopic features of intestinal ulcers and gastrointestinal tumours. These are precise curricular anchors; they do not certify independent competence to diagnose, stage or treat colorectal cancer. A clinically integrated lesson should connect PA23.8 to adenoma-carcinoma and mismatch-repair pathways, gross site patterns, graded adenocarcinoma, invasion depth, lymphovascular and perineural invasion, tumour deposits, margins, nodal yield and metastatic spread. PA23.9 supports supervised specimen and slide interpretation, including distinguishing dysplasia, invasive carcinoma and important inflammatory mimics. History, abdominal examination and digital rectal examination belong in supervised clinical teaching, with consent, privacy and chaperone practice. Investigation teaching should require learners to explain what colonoscopy, biopsy, CT and rectal MRI each contribute rather than reciting a list. Management learning should be framed as multidisciplinary reasoning: separate colon from rectal pathways, localised from metastatic disease, and curative from symptom-directed intent. Communication objectives include explaining uncertainty, a possible stoma and inherited-risk referral without coercion. Assessment can combine a written clinicopathological problem, pathology spotter, staging interpretation and an observed counselling task. The mapping remains deliberately bounded to published competencies and avoids inventing a colorectal surgery competency code that is not named in the curriculum source.
Key Exam Pearls for NEET PG
Think anatomically and pathologically. Right-sided colon cancers more often produce occult blood loss, iron-deficiency anaemia and a mass; left-sided lesions more often alter bowel habit or obstruct; rectal lesions may cause bleeding and tenesmus. These are tendencies, not exclusion rules. Colonoscopy visualises and samples the primary and searches for synchronous lesions. CEA is not a screening or diagnostic test; its useful roles include baseline prognosis and follow-up in an appropriate pathway. Stage colorectal cancer with TNM, and remember that adequate nodal assessment and circumferential resection margin are important pathological concepts. Rectal MRI describes local extent, mesorectal fascia relationship, nodes and other risk features that alter preoperative planning. A normal digital rectal examination cannot exclude a proximal lesion. Lynch syndrome is autosomal dominant and involves mismatch-repair genes; familial adenomatous polyposis involves APC and extensive adenomas. In metastatic colorectal cancer, RAS status predicts lack of benefit from anti-EGFR therapy when mutated, while mismatch-repair deficiency or high microsatellite instability can predict sensitivity to immune-checkpoint therapy. Oxaliplatin is associated with cumulative sensory neuropathy; irinotecan with diarrhoea and myelosuppression; fluoropyrimidines can rarely cause serious early toxicity and cardiotoxicity. Curative treatment is not limited to stage I-III: selected isolated liver or lung metastases may be resectable after multidisciplinary review. Do not reproduce an old chemotherapy algorithm as a current prescription. In an examination answer, stabilise obstruction or perforation first, confirm histology, stage accurately, and then state that definitive planning is multidisciplinary.
Frequently Asked Questions
Does visible rectal bleeding usually mean haemorrhoids rather than colorectal cancer?
Haemorrhoids are common, but their presence does not explain every episode of bleeding and does not exclude a synchronous colorectal lesion. Persistent or unexplained bleeding needs a history, examination and age- and risk-appropriate colonic evaluation, especially when accompanied by altered bowel habit, iron-deficiency anaemia, weight loss, abdominal symptoms or a family history. Urgent instability or heavy bleeding requires emergency care.
Can a normal CEA blood result rule out colorectal cancer?
No. CEA lacks the sensitivity and specificity required to exclude or confirm colorectal cancer. Some confirmed cancers do not raise it, and non-malignant conditions can raise it. Diagnosis depends on visualisation and histopathology, with imaging for stage. A baseline CEA can still be useful for prognosis and later surveillance when interpreted alongside symptoms, examination and imaging.
Why are colon cancer and rectal cancer not treated through one identical pathway?
Their anatomy, local-recurrence risks and surgical constraints differ. Colon cancer usually proceeds to oncological resection followed by stage-based adjuvant decisions. Rectal cancer requires pelvic MRI and assessment of the mesorectal fascia, sphincters and pelvic nodes; selected patients benefit from preoperative radiotherapy and systemic treatment. Both require histology, systemic staging and multidisciplinary review, but the sequence is individualised.
Should an Indian patient follow a foreign colorectal screening or treatment guideline directly?
Not automatically. Foreign guidelines can clarify evidence, but screening thresholds, available tests, medicine approvals, radiotherapy capacity and referral systems may differ. Indian ICMR material adds local context but the colorectal consensus is from 2014 and cannot cover newer therapies. The safe approach is to combine current evidence with an Indian specialist tumour board, local formulary and the patient’s preferences and resources.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic